The GNAS postzygotic mosaic activating mutations involved in fibrous dysplasia and McCune-Albright syndrome (MAS) are not detectable in leukocytes by Sanger sequencing. Digital droplet polymerase chain reaction detects GNAS mutations in 7 of 12 patients (58.3%) suspected to have fibrous dysplasia/MAS from whole blood DNA, and in 4 of 5 patients (80%) from circulating cell-free DNA. (J Pediatr 2019;205:281-5).
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The GNAS postzygotic mosaic activating mutations involved in fibrous dysplasia and McCune-Albright syndrome (MAS) are not detectable in leukocytes by Sanger sequencing. Digital droplet polymerase chain reaction detects GNAS mutations in 7 of 12 patients (58.3%) suspected to have fibrous dysplasia/MAS from whole blood DNA, and in 4 of 5 patients (80%) from circulating cell-free DNA. Fibrous dysplasia may affect 1 bone (monostotic) or multiple bones (polyostotic), and may occur in isolation (fibrous dysplasia disease) or in combination with café-au-lait skin pigmentation and hyperfunctioning endocrinopathies. [1] [2] [3] [4] [5] GNAS encodes for the G-protein alpha subunit, which transduces the signal of many hormonal receptors (including the parathyroid hormone/parathyroid hormone-related protein, follicle-stimulating hormone, thyroidstimulating hormone, adrenocorticotrophic hormone, and growth hormone-releasing hormone receptors). In fibrous dysplasia/MAS, the activating mutations of GNAS are nearly always substitutions of the arginine 201 by cysteine (NM_000516.5: c.601C>T, p.Arg201Cys, rs11554273) or histidine (NM_000516.5: c.602G>A, p.Arg201His, rs121913495), that constitutively activate the G-protein alpha subunit. Herein, we have respectively named these mutations R201C and R201H. MAS endocrine lesions include peripheral precocious puberty (PPP), thyroid abnormalities, growth hormone excess, hypercortisolism, and hypophosphatemia owing to fibroblast growth factor-23 overproduction. 3, [6] [7] [8] [9] The acquisition of mutation during early embryogenesis leads to a mosaic distribution of the lesions.
MAS diagnosis is based on clinical features, but the time lag between the first sign (often PPP at an average of 3-4 years) and the others leads to an important delay of clinical diagnosis. 10, 11 A molecular diagnosis could allow an earlier diagnosis and consequently a follow-up and a therapeutic choice more adapted to the fibrous dysplasia/MAS context, reducing the complications and optimizing the quality of life. Moreover, fibrous dysplasia can require a molecular diagnosis in case of monolesion. However, the mosaic distribution of the GNAS mutations in fibrous dysplasia/MAS makes the molecular diagnosis highly challenging. Moreover, owing to a low level of mosaicism in blood cells, the routine noninvasive methods are insufficiently sensitive.
Consequently, the development of a sensitive and noninvasive test is crucial for an early molecular diagnosis. Digital droplet polymerase chain reaction (ddPCR) is a breakthrough technology of quantitative PCR useful for a targeted detection and quantification of rare events. 12, 13 Moreover, the emergence of the new noninvasive strategy to detect and monitor mutations in the circulating cell-free DNA (ccfDNA) from patients presented with a cancer (named "liquid biopsies") offers new prospects for the molecular diagnosis of fibrous dysplasia/MAS. 14, 15 ccfDNA is fragmented DNA, released in plasma by normal and tumor cells through apoptosis, necrosis, or active secretion, that can be extracted from plasma and detected by sensitive molecular methods. 14, 15 The objective of this study was to evaluate digital PCR for a noninvasive molecular diagnosis of fibrous dysplasia/MAS. For that purpose, we targeted the R201H and R201C GNAS mutations by ddPCR in whole blood DNA and ccfDNA of 17 patients presenting with at least 1 sign of fibrous dysplasia/MAS.
Methods
After a validation study (Figure , Table I , and Appendix; available at www.jpeds.com), we performed targeted study of the R201H and R201C GNAS mutations by ddPCR in the various samples of patients (Table II) . Patients were studied for fibrous dysplasia/MAS mutations in the molecular biology laboratory of Conception's Hospital between January 2001 and December 2016. All patients or their parents provided signed informed genetic consent. DNA was extracted from whole blood collected in EDTA tubes using an automated magnetic-particle technology on the QiaSymphony instrument (Qiagen, Germantown, Maryland). DNA from tissues was manually extracted using QiAmp DNA mini kits (Qiagen) following the manufacturer's instructions. ccfDNA was extracted from cell stabilizing blood collection tubes (Cell-Free DNA BCT, Streck, Omara, La Vista, Nebraska), using the IDXTRACT kit (ID-Solutions, Grabels, France).
R201C and R201H ddPCR Mutation Detection Assays
The samples were analyzed using 2 ddPCR Mutation Detection Assays targeting the R201C or the R201H mutations. Each assay used a duplexed TaqMan PCR system with 2 labeled probes: the first, labeled HEX, targeting the wild-type (WT) allele and the second, labeled 6-FAM, targeting the mutant allele. These assays were purchased from Bio-Rad (Hercules, California; the GNAS p.R201C + GNAS WT for p.R201C PrimePCR ddPCR Mutation Detection Assays [named R201C assay in the text] and the GNAS p.R201H + GNAS WT for p.R201H PrimePCR ddPCR Mutation Detection Assays [named R201H assay in the text]). The mixture (reagents + DNA) was emulsified into up to 20 000 oil droplets following the manufacturer's instruction. The droplets were transferred to a PCR plate and amplified by PCR using the following protocol: 10 minutes at 95°C, forty 30-second cycles at 94°C followed by 1 minute at 55°C. The following 10 minutes at 98°C stop the reaction and clot the droplets. After PCR, the fluorescence of each droplet was read on the 200 Droplet Digital PCR System (Bio-Rad).
Statistical Analyses
The results were analyzed using the Quantisoft software (BioRad) to determine the fraction of PCR-positive droplets in the original sample. Poisson statistical analysis of the number of positive and negative reactions permitted the calculation of the absolute amount of WT or mutated alleles in the starting template without standard curves. 12, 16, 17 The results were reported in fractional abundance (FA) corresponding with the percentage of the mutated alleles out of the total alleles (ratio mutated alleles/mutated + WT alleles).
The statistical comparison between methods was performed using a 2-tailed Fisher exact test performed on the Prism 6 Software (GraphPad, San Diego, California).
Results
We studied 16 females and 1 male, 12 of whom were children (average age 6.5 ± 4.2 years [range, 1-12 years]), and 5 adults (average age 43.6 ± 29.3 years [range, 18-71 years] ). Four patients presented with at least 3 fibrous dysplasia/MAS symptoms, 9 patients presented with 2 fibrous dysplasia/MAS signs, and 4 patients presented with 1 fibrous dysplasia/MAS sign ( Table II) . The most common symptom was PPP (14/17). Three patients presented growth hormone excess. Twelve patients were tested only on whole blood DNA. Five patients were tested on both whole blood DNA and ccfDNA.
The R201C or R201H ddPCR analysis on whole blood DNA was positive in 7 of 12 patients (58.3%; Table II ). For 3 patients (patients 2, 5, and 8), a second blood sample or a sample from a fibrous dysplasia/MAS lesion (fibrous dysplasia) was available. The ddPCR analysis of this second sample confirmed the result of the blood one. The FA of the mutated allele ranged from 0.03% to 20.87% in whole blood DNA. No correlation was found between the FA or the rate of detection of GNAS mutants and the number of MAS signs (Table II and  Table III [available at www.jpeds.com]).
The combined analyses on both whole blood DNA and ccfDNA led to a fibrous dysplasia/MAS molecular diagnosis in 4 of 5 patients (80% ; Table II and Table III ). In 1 patient (patient 7), the test was positive on both ccfDNA and whole blood DNA. The FA increased from 0.08% in the whole blood sample to 1.7% in ccfDNA. In 3 patients (patients 3, 6, and 17), the test was positive only on ccfDNA. These patients corresponded with 3 girls-a 6-year-old presenting with café-au-lait skin pigmentation and PPP, a 12-year-old presenting the classic MAS triad, and a 2-year-old with PPP. For child number 6, a skin lesion was obtained at the same time. DdPCR analysis run on it found the R201C mutant allele, confirming the results obtained on ccfDNA. The test of the fifth patient (patient 14) was negative on both whole blood DNA and ccfDNA.
We compared the performance of the 2 strategies, one using ddPCR on whole blood DNA alone and the other using ddPCR on whole blood DNA plus ccfDNA, with the performance of the 4 published methods (Table IV) . 11, 18, [20] [21] [22] [23] Despite the small number of patients in our series, the number of ddPCR diagnoses was higher than those using nested PCR (P < .05; Table IV ). The ddPCR performance was also higher than those of mutant enrichment with 3′-modified oligonucleotides (MEMO)-PCR and peptide nucleic acid (PNA) clamping but without reaching the threshold of significance and was similar to the PNA-next-generation sequencing (NGS , Table IV ).
Discussion
Fibrous dysplasia/MAS results from postzygotic GNAS mutations that are not detectable in peripheral blood leukocytes by Sanger sequencing. Biopsies in café-au-lait spots or bone lesions are rarely available. 10 Currently, a definitive diagnosis of fibrous dysplasia/MAS is often supported by the clinical triad of fibrous dysplasia/MAS signs and less frequently by a molecular analysis of bone biopsies. When the triad is incomplete, it is difficult to recommend the performance of an invasive and painful medical procedure on children with no direct benefits. Moreover, the molecular analysis of skin biopsies generally turns out negative. 19 The early diagnosis of fibrous dysplasia/MAS should allow for the early treatment of lesions and the prevention of complications, especially for somatotroph tumors, for which the treatment is often exclusively medical, owing to frequent invasive pituitary adenomas and the presence of fibrous dysplasia at the skull base. 9, 24 A noninvasive molecular diagnosis of fibrous dysplasia/ MAS was an unmet medical need that required new, more sensitive and cost-effective tools. In this study, we validated the ddPCR as an inexpensive method to perform a noninvasive molecular diagnosis of fibrous dysplasia/MAS during early childhood. First, we validated ddPCR as an accurate and reliable method to carry out a positive diagnosis of fibrous dysplasia/MAS, following international guidelines (Appendix). 25 We assessed the specificity of both assays using limit of blank (LOB) tests, which showed no false-positive results (Figure and Appendix).
In our series of 12 patients for whom fibrous dysplasia/ MAS was suspected, ddPCR from whole blood DNA detected an R201H or R201C mutation in 58.3% (7/12 patients; Table II ). For several years, teams have been developing molecular methods more sensitive than Sanger sequencing to detect rare molecular events in peripheral blood leukocytes DNA, such as the R201H and R201C GNAS mutant alleles in fibrous dysplasia/MAS. These methods-nested PCR, PNA clamping, PCR, and mutant enrichment with 3′-modified oligonucleotides PCR-are based on the enrichment of the mutant allele vs the WT by enzymatic digestion or by masking the WT allele. 11, 22, 23 In a series of 88 patients, including 26% of patients with 3 signs of fibrous dysplasia/MAS, Kalfa et al obtained a detection rate in blood leukocytes of 35.2% using PNA clamping and 36.6% using nested PCR. 18 The mutant enrichment with 3′-modified oligonucleotides PCR, published recently, succeeded in finding genetic abnormality in blood DNA of only 2 of 7 patients. 11 The ddPCR displayed the highest detection rate in whole blood DNA, with 58.3% of molecular proof of MAS regardless of the number of MAS signs and 67% of patients with the 2 or 3 fibrous dysplasia/MAS signs ( Table IV) . The ddPCR performance in patients with only 1 or 2 signs of fibrous dysplasia/MAS is particularly promising in comparison with the other methods.
The combined real-time coamplification at lower denaturation temperature and mismatch amplification mutation assay PCR techniques showed a sensitivity of 0.05% for the detection of the R201C and R201H GNAS mutations, which is similar to that of the nested PCR method but lower than ddPCR evaluated at 0.01% (Appendix). 18, 26 This robust method used inexpensive techniques but remains to be clinically evaluated on patients with suspected fibrous dysplasia/MAS.
For routine use, the increase in the sensitivity of the method should not be obtained owing to a steep increase in detection laboratory costs, as for PNA-NGS. The PNA-NGS technique combines an ultradeep NGS with the PNA clamping (for this method, see legend of Table IV) . 20 In the clinical evaluation study in MAS-suspected patients, the rate of GNAS mutant detection was 75% (12/16), including 8 of the 8 patients with the MAS triad and 4 of the 8 patients with 2 major fibrous dysplasia/MAS signs. NGS-PNA was as sensitive as ddPCR, but the authors disclosed that they could not discriminate true positives from false positives, which required analysis of paired peripheral blood leukocyte-affected tissues samples. Our validation study of ddPCR displayed a specificity at 100%, offering a more robust diagnosis. Additionally, ddPCR offers a 1-day analysis after DNA extraction for acceptable reagent cost (10€ per PCR well).
The origin of the GNAS mutated DNA in blood remains unclear. Three possibilities can be hypothesized considering that the routine DNA extraction from whole blood samples collects all DNA types (from nuclear cells or free-cell DNA). DNA should originate from leukocytes bearing a mosaic GNAS mutation, ccfDNA from fibrous dysplasia/MAS lesions, or circulating tumor cells. In this context, we performed a GNAS analysis on both blood DNA and ccfDNA. We found R201H and R201C mutants in 4 of the 5 analyzed patients (80%). For 3 of these 4 patients, whole blood analysis was negative by ddPCR, and for the fourth patient, the analysis was positive. For this patient (patient 7), the FA of the mutant in ccfDNA ) . The results are expressed in percentage of positive patients (n of positive/n of total tested patients). Statistical analyses: 2-tailed Fisher exact test vs nested PCR. MEMO-PCR is an enrichment PCR method based on the use of a 3'-modified oligonucleotide primer that blocks extension of the normal allele but enables extension of the mutated allele. PNA clamping is based on the inhibition of the WT allele amplification. The PNA primer that is complementary to the WT sequence overlaps the binding site of the PCR primer and prevents amplification of the WT allele. The PNA primer will not bind to the mutant sequence, and the mutant allele is thus amplified during PCR. NGS-PNA combined PNA-clamping and ultradeep NGS. *P < .05.
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Volume 205 was 20-fold higher than the FA in whole blood DNA (0.08% vs 1.70%), suggesting a concentration of genetic information in ccfDNA thanks to the removal of the leukocyte genomic DNA (Table II and Table III) . By performing a combined test on whole blood DNA and on ccfDNA, we successfully increased the sensitivity of genetic screening from 58.3% to 80.0%. This combined strategy allows a diagnostic performance similar to that of PNA-NGS (12/16 and 4/5, respectively). However, ccfDNA testing requires removing a blood sample from a specific tube (cell-free DNA tube) not available for all clinical centers. That explained why we prefer to recommend a whole blood DNA ddPCR testing in the first step and, if negative, to test on ccfDNA. This strategy should be further evaluated on a larger series of patients with fibrous dysplasia/MAS. 
Materials and Methods
The ability of both ddPCR assays to detect mutations was assessed using the DNA extracted from somatotroph adenomas, previously characterized with the presence of heterozygous R201C or R201H GNAS mutations by Sanger sequencing. The accuracies of the R201C and R201H assays were assessed by determining the LOB. For that, regular DNA not harboring the targeted mutant alleles was analyzed through 40 technical replicates. Additionally, the repeatability of the quantitative measurement was evaluated by measuring concentrations of the WT DNA copies in the LOB test.
Subsequently, positive controls provided from 2 somatotroph tumors were introduced in each run for technical validation and also used to determine the reproducibility and the accuracy of the test.
We performed biological validation by working blindly on the DNA of various samples extracted from patients previously characterized by nested PCR method for the presence of GNAS mutations. nested PCR uses a modified primer to obtain a PCR product from normal DNA that can be digested by a restriction enzyme (EagI), whereas the PCR product obtained from mutated DNA is resistant to this enzyme. The successive completion of the PCR steps and enzyme digestion results in an enrichment of the mutated allele. 2, 3 In this series, DNA was extracted from blood or from fresh tissues.
Results

Technical Validation of ddPCR.
In the 2 mutated DNA samples from the somatotroph tumors (positive controls), ddPCR detected the R201H or R201C mutant alleles (Table I ; available at www.jpeds.com). The specificity of both R201C and R201H assays was considered to be 100% since no positive droplet for the mutant was detected in any of the 40 PCR wells containing only normal genomic DNA (LOB test; Figure  [ available at www.jpeds.com]). The test was therefore considered positive if there was at least 1 positive droplet for the mutant allele and negative if there were only positive droplets for the WT allele. The repeatability of each assay was assessed by measuring the WT DNA concentration in the LOB test with an input of 50 ng of DNA and were, respectively, 670 ± 40 copies/µL (mean ± SD) for the R201C assay and 673 ± 49 WT copies/µL for the R201H assay. The variation coefficients) were respectively 6.7% and 5.6%. The inter-run accuracy was determined and monitored using the FA of the somatotroph pituitary adenoma positive controls during the subsequent tests: the variation coefficient was 3.2% for the detection of the R201C mutant and 2.5% for the R201H mutant.
Comparison between the ddPCR Method and the Nested PCR Method. To validate ddPCR, we compared the results obtained blindly by ddPCR with those obtained previously by nested PCR on 34 samples from 18 patients, published 14 years ago (Table I ; available at www.jpeds.com 3 ). ddPCR analysis confirmed the molecular diagnosis of MAS given by nested PCR for all the patients suffering from MAS. The lack of R201H or R201C mutant alleles was confirmed using ddPCR in 10 of 10 patients negative for a GNAS mutation with the nested PCR method. For 2 patients (T1 and T4) for whom several samples were available, the results from the 2 techniques showed discrepancies depending on the samples. In the DNA from patient T1, ddPCR showed an R201H mutation in blood, whereas this result was negative in nested PCR. Nevertheless, an R201C mutation was also carried out by ddPCR for this patient. The lowest detectable mutation abundance was 0.01% with ddPCR.
Discussion and Conclusion
Our aim was to validate ddPCR as an accurate and reliable method to carry out a positive diagnosis of fibrous dysplasia/ MAS. First, we assessed the specificity of both assays using LOB tests, which showed no false positive. Then, we used a cohort of 18 patients previously analyzed independently by the nested PCR method. The amount of positive and negative results for patients screened with the 2 techniques matched well, despite the fact that DNA samples were old and had been previously tested 12 years ago. Fibrous dysplasia/MAS molecular diagnosis was confirmed by ddPCR for the 7 patients previously diagnosed by nested PCR and fully analyzed by ddPCR. The lowest detectable mutation abundance was 0.01% with ddPCR. The main advantage of ddPCR in comparison with nested PCR is a decreased risk of contamination by PCR product and a decreased analysis time, namely, 4 days for nested PCR vs 1 day for ddPCR. 4 In patient T1, ddPCR gave a positive result for the blood DNA and ovarian DNA samples, but a negative result for the blood DNA sample with nested PCR, thus suggesting a higher sensitivity of the ddPCR assay. 
